| Autor: |
David E. Fisher, Bradley E. Bernstein, Leonard I. Zon, Julia Newton-Bishop, Jian Jin, Yan Xiong, Brian B. Liau, C. Thomas Powell, Whitney Silkworth, Yang Feng, Yao Zhan, Lajos V. Kemeny, Ellen van Rooijen, Jennifer A. Lo, Nhu Nguyen, Yotam Drier, Joey Mark S. Diaz, Joanna Pozniak, Sathya Muralidhar, Kevin Y. Chen, Megan L. Insco, Qing Yu Weng, Shinichiro Kato |
| Rok vydání: |
2023 |
| DOI: |
10.1158/2159-8290.c.6547855.v1 |
| Popis: |
Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a histone methyltransferase gene, as well as G9a genomic copy gains in approximately 26% of human melanomas, which collectively drive tumor growth and an immunologically sterile microenvironment beyond melanoma. Furthermore, the WNT pathway is identified as a key tumorigenic target of G9a gain-of-function, via suppression of the WNT antagonist DKK1. Importantly, genetic or pharmacologic suppression of mutated or amplified G9a using multiple in vitro and in vivo models demonstrates that G9a is a druggable target for therapeutic intervention in melanoma and other cancers harboring G9a genomic aberrations.Significance:Oncogenic G9a abnormalities drive tumorigenesis and the “cold” immune microenvironment by activating WNT signaling through DKK1 repression. These results reveal a key druggable mechanism for tumor development and identify strategies to restore “hot” tumor immune microenvironments.This article is highlighted in the In This Issue feature, p. 890 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
